Jiangsu Lianhuan Pharmaceutical (600513.SH) subsidiary obtains registration certificate for the drug Amlopidine Besilate tablets.

Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that its holding subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd. (referred to as "Changle Pharmaceutical"), recently received the Drug Registration Certificate issued by the National Medical Products Administration for the drug Losartan Potassium Tablets. Losartan Potassium Tablets can be used to treat primary hypertension in adults. This time, Changle Pharmaceutical obtained the Drug Registration Certificate for Losartan Potassium Tablets (40mg/80mg), further enriching the company's and its subsidiaries' product lines and helping to enhance the market competitiveness of the company and its subsidiaries. The acquisition of the Drug Registration Certificate is expected to have no significant impact on the company and its subsidiaries' recent operational performance.